CRISPR enzyme destroys cancer cells by shredding their DNA

AI Insight

Researchers have identified a CRISPR-associated enzyme with the ability to destroy cancer cells by fragmenting their DNA. The protein can be directed specifically toward cells containing tumor-causing mutations, offering a targeted approach to cancer treatment. Early experimental tests demonstrate the enzyme's potential effectiveness in selectively eliminating malignant cells.

Why it matters

This discovery could lead to more precise cancer therapies that target only cells with specific cancer-causing mutations while sparing healthy tissue. The targeted DNA-shredding mechanism represents a potentially new class of cancer treatment distinct from traditional chemotherapy or existing gene-editing approaches.